Stock TGTX TG THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Real-time Estimate Cboe BZX
Other stock markets
 02:55:48 2024-05-01 pm EDT 		5-day change 1st Jan Change
16.33 USD +19.55% Intraday chart for TG Therapeutics, Inc. +14.09% -6.62%
03:33pm Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts MT
01:08pm Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts
MT
TG Therapeutics: Q1 Earnings Snapshot
AQ
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M
MT
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
AQ
North American Morning Briefing : Investors Brace -2-
DJ
TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
MT
Sector Update: Health Care
MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi
MT
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
AQ
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis
CI
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing
MT
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
AQ
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile
MT
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TGTX Stock
  4. News TG Therapeutics, Inc.